Retraction Note: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level (Archives of Gynecology and Obstetrics, (2004), 269, 2, (125-129), 10.1007/s00404-002-0437-x);A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

Archives of Gynecology and Obstetrics

Volumn 269, Issue 2, 2004, Pages 125-129

  Parsanezhad, Mohammad Ebrahim ^a,b   Alborzi, Saeed ^a   Jahromi, Bahia Namavar ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Germany)

Author keywords

Bromocriptin; Clomiphene citrate resistant; Polycystic ovary; Prolactin

Indexed keywords

BROMOCRIPTINE; CLOMIFENE CITRATE; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY CYCLE; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PREGNANCY; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0742271274     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-023-07330-z     Document Type: Erratum

References (23)

1. Branigan EF, Estes MA (1999) Treatment of chronic anovulation resistant to clomiphene citrate(CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment. Fertil Steril 71:544-546
2. Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Beuscart R, Fossati P (1986) A double blind controlled study of the hormonal and clinical effects of bromocriptin in the polycystic ovary syndrome. Clin Endocrinol Metab 63:119-124
3. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Janni A (1984) Polycystic secretion in polycystic ovary syndrome: Correlation with the steroid pattern. Acta Endocrinol 105:99-104
4. Chapman AJ, Wilson MD, Obhari M, Sawers RS, Lynch SS, Royston JP, Clayton RN (1987) Effects of bromocriptin on LH pulsatility in the polycystic ovary syndrome. Clin Endocrinol 27:571-580
5. Corenblum B, Taylor PJ (1980) A rational for the use of bromocriptin in patients with amenorrhea and normoprolactinemia. Fertil Steril 34:239-241
6. Ergur A (1998) Clomiphene citrate resistant polycystic ovary syndrome. J Reprod Med 43:185-190
7. Falashi P, Del Pozo E (1986) Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 62:348-351
8. Falashi P, Del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese J (1980) Prolactin release in polycystic ovary. Obstet Gynecol 55:579-582
9. Futterweit W, Krieger DT (1979) Pituitary tumors associated with hyperprolactinemia and polycystic ovarian disease. Fertil Steril 31:608-613
10. Kaptien EM, Kletzky DA, Spencer CA, Noolof JT (1980) Effects of prolonged dopamine infusion on anterior pituitary function. JCE & M 43:488-491
11. Kubota T, Kamada S, Aso T (1992) Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Int J Fertil 37:277-282
12. Lunde O (1981) Hyperprolactinemia in polycystic ovary syndrome. Ann Chir Gynaecol 70:197-201
13. Marco C (1998) Effects of clomiphene citrate on androgens in polycystic ovary syndrome. Archiv Gynecol Obestet 261:117-120
14. Mitwally FM, Casper RF (2001) Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75:350-359
15. Peilon F, Vincens M, Ceselin F, Doumit R, Mouszowics I (1982) Exaggerated prolactin response to thyrotropin-releasing hormone in women with anovulatory cycles: Possible role of endogenous estrogens and effect of bromocriptine. Fertil Steril 37:530-535
16. Prelevic GM, Wurzburger MI, Peric LA (1987) Acute effects of L-dopa and bromocriptin on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. J Endocrinol Invest 10:389-395
17. Rosato P, Minto F, Garrone S, Ragni N (2000) Growth hormone response to clomiphene in anovulatory infertile women resistant to clomiphne citrate stimulation. Fertil Steril 73:78-84
18. Siginami H, Hamada K, Yano K, Kuroda G (1986) Ovulation induction with bromocriptin in noroprolactinemic anovulatory women. JCE & M 62:899-903
19. Speroff L, Glass RH, Kase NG (1999) Anovulation and the polycystic ovary syndrome. Clinical gynecologic endocrinology and infertility, 6th edn. Williams and Wilkins, Baltimore, pp 487-521, 1105
20. Spruce BA, Kenedal Taylor P, Donlope W, Anderson AJ, Watson MJ, cook DB et al (1984) The effect of bromocriptin in the polycystic ovary syndrome. Clin Endocrinol 20:481-488
21. Steingold KA, Lobo RA, Judd HL, Lu JK, Chang RJ (1986) The effect of bromocriptin on gonadotropin and steroid secretion in polycystic ovarian disease. Clin Endocrinol Metab 62:1048-1051
22. Takakura K, Taii S, Ihara Y, Takai I, Mori T (1989) Aggravation of inappropriate lutenizing hormone secretion by bromocriptin in polycystic ovary syndrome with elevated serum DEHAS. Endocrinol Jpn 36:261-268
23. Worstman J, Hirschowitz JS (1980) Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet Gynecol 55:460-463